Business
Amylin’s Offering a Success: On its first day of public trading, Amylin Pharmaceuticals shares closed at $20.75 over the counter, up sharply from Friday’s initial offering price of $14.
Jan. 18, 1992
Amylin Pharmaceuticals Inc. said Daniel M.
June 8, 2006
Ailing Amylin Pharmaceuticals Is Trying to Craft a Drug to Control Diabetes and Bring Itself Back to Good Health
May 24, 1999
Dr. Robert Butz has joined Amylin Pharmaceuticals as vice president of development.
Jan. 14, 1992
Science & Medicine
Amylin Pharmaceuticals said Tuesday that its top drug prospect, Symlin, has been able to improve blood sugar control and promote weight loss in patients with adult-onset diabetes.
Sept. 1, 1999
Drugs: Industry giant will pay up to $325 million, help promote the biotech company’s experimental diabetes treatment and share the profit.
Sept. 21, 2002
* Amylin Pharmaceuticals Inc. shares fell as much as 83% one day after the company reported a setback in its development of an experimental diabetes drug and said its stock may be delisted from Nasdaq.
Oct. 22, 1998
Bristol-Myers to acquire diabetes drug maker Amylin
June 30, 2012
Amylin Pharmaceuticals Inc. said the Securities and Exchange Commission was conducting an informal inquiry related to communications about the company’s Symlin injectable drug for blood-sugar control.
Dec. 20, 2003
Amylin Pharmaceuticals Inc. shares fell as much as 83% one day after the company reported a setback in its development of an experimental diabetes drug and said its stock might be delisted from Nasdaq.